Adverse somatic mutations including ASXL1, RUNX1, TP53 or EZH2 significantly impact on the prognosis of MDS patients [1] and established therapeutic concepts have only limited efficacy in this patient population [2–4]. This evidence concerns the gene EZH2 and myelodysplastic syndrome.